CPT® Code 20605

Last Updated: February 2026 | Verified for 2026 AMA, CPT & CMS Guidance (Coding, Coverage & Documentation)

Quick Reference: CPT 20605 (Arthrocentesis, Intermediate Joint/Bursa)

• What 20605 means: Arthrocentesis (aspiration and/or injection) of an intermediate joint or bursa without ultrasound guidance. Typical examples include wrist, elbow, ankle, temporomandibular (TMJ), acromioclavicular (AC) joint, and olecranon bursa.
• One unit per joint, per session: The descriptor “aspiration and/or injection” means you do not bill separately for aspiration and injection in the same joint during the same encounter; report one unit per joint treated.
• Ultrasound changes the code: If ultrasound guidance is used and documented according to CPT requirements, report the corresponding with ultrasound arthrocentesis code (for intermediate joint, that is 20606), rather than 20605. Ultrasound guidance should not be billed separately when using the “with US” arthrocentesis code.
• Laterality matters: Use RT/LT for unilateral injections and follow payer instructions for bilateral reporting (often modifier 50 or two lines with RT/LT). Clear laterality prevents duplicate denials for multiple joints of the same CPT code on the same date.
• Documentation drives payment: Payers focus on joint/site, indication, conservative therapy history (when relevant), medication injected (if any), and whether imaging guidance was used. Documentation must make the billed code auditable.
• Coverage varies by injected substance: For hyaluronan (viscosupplementation), many coverage rules are more restrictive than for corticosteroid injections; Medicare coverage is implemented via CMS coverage articles and payer policies vary (including some plans ending coverage). CPT 20605 is the primary code for arthrocentesis (aspiration and/or injection) of an intermediate-sized joint or bursa when performed without ultrasound guidance. In 2026, the main payment and audit risks for 20605 are predictable: (1) choosing the wrong joint-size code (20600 vs 20605 vs 20610), (2) billing 20605 when ultrasound guidance was actually used (or vice versa), (3) unbundling aspiration and injection in the same joint, and (4) failing to signal distinct joints/laterality when multiple injections are performed on the same date. This article provides a payer-realistic, documentation-forward approach to billing 20605 defensibly in 2026.

1. Definition and Procedure Scope

CPT 20605 describes arthrocentesis of an intermediate joint or bursa performed without ultrasound guidance. Arthrocentesis includes aspiration (removal of synovial or bursal fluid) and/or injection (delivery of medication into the joint or bursa). The “and/or” language is operationally important: aspiration alone, injection alone, or aspiration followed by injection into the same joint during the same session is still reported as one unit of 20605 per joint.

Intermediate joint examples commonly cited in coding references include the wrist, elbow, ankle, temporomandibular joint (TMJ), acromioclavicular (AC) joint, and olecranon bursa. These examples are not merely educational; they are central to choosing the correct code when payers compare the billed CPT to the documented anatomy.

Clinically, 20605 is used for two main categories of service:

• Diagnostic arthrocentesis: aspiration of fluid for diagnostic evaluation (e.g., suspected crystal arthropathy, inflammatory arthritis flare, or possible infection evaluation when clinically appropriate). The procedural code captures the aspiration; laboratory analysis of aspirated fluid is reported separately as applicable.
• Therapeutic arthrocentesis/injection: injection of medication such as corticosteroid or anesthetic into an intermediate joint/bursa to reduce pain and inflammation and improve function. The medication itself is billed separately when appropriate (for example, HCPCS drug codes when supplied by the billing entity). Compliance boundary: 20605 is the procedure (needle entry and aspiration/injection service). It is not a proxy for the medication. If a substance is injected and separately payable, the drug is billed on its own line according to payer rules and site-of-service responsibility.

2. Joint Classification: 20600 vs 20605 vs 20610

The most common technical error with arthrocentesis coding is selecting the wrong joint-size family code. CPT divides arthrocentesis into three joint-size categories and a parallel set of “with ultrasound” codes. For 20605, accurate joint classification is non-negotiable because payers may treat “wrong joint-size code” as incorrect coding even when the service was clinically appropriate.

A frequent real-world confusion is shoulder-region injections. The acromioclavicular (AC) joint is an intermediate joint (20605), while the glenohumeral joint is a major joint (20610). When documentation states “AC joint injection,” billing 20610 is a mismatch that can trigger downcoding or post-payment audit risk.

3. Documentation Standards and Required Elements

Documentation is the main determinant of whether 20605 is defensible in medical necessity review. Auditors and payers typically test two questions:

(1) Was arthrocentesis clinically justified? and

(2) Does the documentation support the exact code billed (joint category and imaging guidance status)?

Practical documentation expectations are summarized in physician-facing coding guidance, with emphasis on an auditable procedure note and clarity on ultrasound use.

3.1 Minimum documentation elements

• Anatomic site (joint/bursa): Specify the exact joint or bursa treated (e.g., “left ankle joint,” “right olecranon bursa”).
• Laterality: Right vs left must be explicit when applicable to support RT/LT or bilateral reporting.
• Indication and medical necessity: Symptoms and findings that justify the procedure (e.g., swelling/effusion, pain limiting function, suspected bursitis, inflammatory flare).
• Conservative therapy history when relevant: For some treatment pathways (especially viscosupplementation), payers frequently expect documentation of prior conservative management and/or prior steroid injection.
• What was performed: Aspiration, injection, or aspiration + injection. If aspiration, note whether fluid was obtained and volume/appearance when clinically relevant.
• Medication injected: Name and dose (and sometimes concentration), especially for steroid/anesthetic injections. Medication documentation should reconcile with drug billing where applicable.
• Guidance statement: Explicitly state whether ultrasound guidance was used. If none was used, documenting “no ultrasound guidance” reduces ambiguity and supports 20605.
• Patient response/complications: Any immediate tolerance issues or adverse events; this becomes important if a discontinued procedure modifier is used. Practical audit-proofing tip: When multiple arthrocenteses occur on the same date, the procedure note should read like separate, clearly delineated services (distinct joint/site + laterality + separate indications or clearly separate anatomic targets). This supports separate line reporting and any distinctness modifiers when required.

3.2 “One unit per joint” and why unbundling fails

The language “aspiration and/or injection” is a built-in bundling rule for the same joint in the same session. If a clinician aspirates an elbow effusion and then injects corticosteroid into that same elbow during the same encounter, the correct reporting is one unit of 20605 for that elbow, not separate aspiration and injection codes. This is a common overcoding pattern and is difficult to defend because the bundling is explicit in the descriptor family logic.

4. Ultrasound Guidance Rules and When 20605 Is Not Appropriate

The single most important technical branch point is whether ultrasound guidance was used and documented in a manner consistent with CPT requirements. When ultrasound guidance is performed for an intermediate joint arthrocentesis and properly documented, the appropriate arthrocentesis code is the “with US” version rather than 20605. Ultrasound guidance is incorporated into the “with US” arthrocentesis code and is not reported separately in that context.

If the clinician used ultrasound but did not meet documentation requirements typically associated with ultrasound-guided procedures (including image retention and documentation of guidance), payers may deny the “with ultrasound” arthrocentesis code on medical record review. In those circumstances, billing may be forced back to the non-ultrasound code family, but the safest operational approach is to align the claim with what the record can support.

Documentation reality: Payers do not adjudicate based on what was “probably done.” They adjudicate based on what is documented and auditable. If ultrasound guidance is used routinely in a practice, standardize documentation templates to reliably support the correct code family.

5. Medicare and Commercial Coverage Realities (Including Viscosupplementation)

Coverage for the procedure (arthrocentesis) is generally broad when medically necessary. However, coverage for the injected substance (particularly hyaluronan viscosupplementation) is often substantially more restrictive and highly policy-driven. In practice, many denials attributed to “20605” are actually driven by the drug policy and the diagnosis/coverage pathway associated with the injected product rather than the needle service itself.

5.1 Medicare: CMS coverage articles and the documentation/interval logic

For Medicare, local and operational rules for intra-articular hyaluronan injections are commonly implemented through CMS coverage articles that specify coding and billing expectations (including interval logic and series concepts). These materials frequently control claim outcomes when hyaluronan products are billed and should be treated as primary operational references for claims teams that bill viscosupplementation.

Even when arthrocentesis itself is covered, Medicare and Medicare Advantage plans may scrutinize repeated injections, clinical rationale, and whether the diagnosis supports the billed therapy. If the record does not support ongoing benefit, repeat injections can become vulnerable to “not reasonable and necessary” determinations.

5.2 Aetna and UnitedHealthcare: typical step-therapy posture for hyaluronan

Large commercial payers commonly require evidence of osteoarthritis and prior conservative management before approving hyaluronan products. Aetna’s clinical policy bulletin for viscosupplementation is a canonical example of step-therapy logic and coverage narrowing around these products.

UnitedHealthcare’s sodium hyaluronate policy similarly describes coverage in defined scenarios and characterizes other uses as not medically necessary under its policy framework. These drug policies frequently drive whether the associated injection encounter is cleanly paid or becomes a denial/appeal workflow.

5.3 Blue Cross policy shifts: why payer volatility matters in 2026

In 2026 planning, practices should explicitly account for payer volatility regarding viscosupplementation. Some plans have announced coverage changes that may eliminate benefits for viscosupplementation for osteoarthritis for certain member populations. When such a policy change applies, even flawless procedural coding and documentation will not convert a non-covered benefit into a covered one; the workflow needs patient counseling, benefit verification, and financial policy alignment.

5.4 TMJ considerations and “intermediate joint” implications

The TMJ is frequently treated as an intermediate joint for arthrocentesis coding purposes, but payer coverage for TMJ-related interventions can be complex and sometimes restrictive depending on the specific service and diagnosis category. For teams dealing with TMJ disorder interventions, it is common to need payer-specific medical policy review when services extend beyond straightforward arthrocentesis/injection and enter procedural TMJ surgery or other covered/non-covered categories.

6. Modifier Usage: 25, 59/X{E,S,U,P}, RT/LT, 50

Most arthrocentesis denials in otherwise-covered cases are technical: missing modifier 25 for a separately billable E/M, missing laterality, or failing to distinguish multiple joints billed with the same CPT code on the same date. Physician-facing coding guidance emphasizes the practical use of these modifiers and the underlying documentation logic that must support them.

6.1 Modifier 25 (on the E/M code, not on 20605)

Use modifier 25 on the E/M service when a significant, separately identifiable evaluation and management service occurs on the same date as the arthrocentesis. The E/M documentation should show work beyond the inherent pre-procedure assessment. If the visit is solely for a planned injection with minimal additional evaluation, billing a separate E/M is typically not supportable.

6.2 RT/LT and bilateral reporting (modifier 50 when required)

Laterality modifiers (RT/LT) are a high-yield denial-prevention tool. For bilateral intermediate joint injections (e.g., both wrists), payers often require a bilateral reporting method (commonly modifier 50 or two-line RT/LT reporting, depending on payer). The claim must unambiguously communicate laterality to prevent the second line from denying as a duplicate.

6.3 Modifier 59 and X-modifiers for multiple distinct joints on the same date

When multiple arthrocenteses are performed on the same date using the same CPT code (e.g., left wrist and left ankle, both intermediate joints), some payer systems treat the second line as a duplicate unless a distinctness modifier is applied. In those cases, modifier 59 (or an appropriate X-modifier where accepted) may be required to identify a distinct anatomic site/structure. Documentation must support distinct joints/structures; modifiers should not be used to bypass the “one unit per joint per session” rule.

Modifier integrity rule: Modifiers communicate clinical reality. If the note does not clearly support distinct joints or distinct encounters, modifier use becomes indefensible in audit.

7. Facility vs Office Workflows and Claim Hygiene

Arthrocentesis claims are often cleanest when the billing workflow matches the site-of-service economics and responsibility for supplies/medications:

• Office (non-facility): The practice typically bills the procedure and, when applicable, the medication administered (subject to payer rules and correct units). Documentation should reconcile to inventory and medication selection.
• Facility (hospital outpatient/ASC): The facility often bills supplies and drug, while the clinician bills the professional service. Splitting responsibilities incorrectly can cause denials (duplicate billing) or compliance risk. Because payer drug policies (especially for hyaluronan) frequently drive approvals/denials, many organizations treat injection visits as a two-step process: (1) benefit and policy validation, then (2) scheduling and delivery with standardized documentation. This reduces avoidable denials and patient dissatisfaction when a drug is non-covered under plan policy.

8. Real-World Scenarios

Scenario 1: Olecranon bursitis aspiration and steroid injection (same bursa)

Setting: Physician office

Service: Aspiration of olecranon bursa fluid followed by corticosteroid injection into the same bursa during the same encounter, without ultrasound guidance.

Coding logic: Report 20605 once for the bursa (aspiration and/or injection is one unit per joint/bursa per session). Bill the steroid drug code separately if supplied by the practice and payable under the payer’s rules.

Documentation tip: Specify “olecranon bursa,” laterality, whether fluid was obtained, medication/dose injected, and explicitly note “no ultrasound guidance.”

Scenario 2: Two intermediate joints on the same side (wrist and ankle)

Setting: Office or outpatient clinic

Service: Left wrist injection and left ankle injection on the same date (both intermediate joints), without ultrasound guidance.

Coding logic: Two lines of 20605 with appropriate laterality, and apply a distinctness modifier (e.g., 59 or payer-accepted X-modifier) to the second line if the payer treats the second line as a duplicate absent a distinctness signal.

Documentation tip: Separate site statements and clearly delineated procedure elements for each joint are essential to support distinct billing.

Scenario 3: AC joint injection vs glenohumeral shoulder injection

Setting: Orthopedic clinic

Service: Injection documented as “AC joint injection” without ultrasound guidance.

Coding logic: AC joint is an intermediate joint, supporting 20605 rather than 20610. Selecting 20610 when the record clearly states AC joint creates mismatch risk.

Documentation tip: Avoid ambiguous shorthand (“shoulder injection”) when AC joint is intended; specify AC joint explicitly to align clinical record and code selection.

Scenario 4: Hyaluronan injection encounter (policy-driven risk)

Setting: Outpatient orthopedic practice

Service: Intra-articular hyaluronan injection series for osteoarthritis (payer-dependent coverage).

Coding logic: The arthrocentesis code (20605/20610 depending on joint size; many viscosupplementation series involve major joints such as knee) must be paired with drug policy compliance and interval logic as applicable. Coverage is frequently contingent on documented conservative therapy and payer-specific criteria.

Operational tip: Verify benefit coverage and policy prerequisites before scheduling series injections; payer policies may characterize some uses as not medically necessary or end coverage for certain populations.

9. High-Frequency Errors and Denial Patterns

• Unbundling aspiration + injection in the same joint: Billing separate services when the descriptor already bundles aspiration and/or injection for the same joint/session is a classic overcoding failure point.
• Wrong joint-size code: AC joint miscoded as major joint (20610) is a common mismatch; documentation that clearly states AC joint makes the miscoding conspicuous.
• Ultrasound used but billed as “without ultrasound” (or vice versa): If ultrasound is used, billing should align with the correct code family and documentation requirements; otherwise, medical record review can drive recoupment or denial.
• Missing laterality or distinctness signaling: Multiple 20605 lines on the same date often need RT/LT and sometimes a distinctness modifier to avoid duplicate denial logic in claims systems.
• Policy mismatch for viscosupplementation: Denials frequently arise from drug coverage criteria rather than the arthrocentesis itself; payer criteria and benefit changes can control outcomes even with correct procedural coding. Best defensive posture in 2026: Standardize arthrocentesis documentation templates (site, laterality, guidance statement, medication/dose), implement payer policy checks for injected substances when relevant, and train staff on joint-size coding (especially AC joint vs shoulder joint).